Head-To-Head Analysis: Catalyst Pharmaceuticals (NASDAQ:CPRX) vs. Bicycle Therapeutics (NASDAQ:BCYC)

Bicycle Therapeutics (NASDAQ:BCYC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Institutional & Insider Ownership

36.3% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 59.8% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.7% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Bicycle Therapeutics and Catalyst Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bicycle Therapeutics -342.94% -238.49% -32.70%
Catalyst Pharmaceuticals 12.99% 15.53% 12.74%

Earnings & Valuation

This table compares Bicycle Therapeutics and Catalyst Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bicycle Therapeutics $7.14 million 21.34 -$21.85 million N/A N/A
Catalyst Pharmaceuticals $500,000.00 939.82 -$34.00 million ($0.33) -13.82

Bicycle Therapeutics has higher revenue and earnings than Catalyst Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Bicycle Therapeutics and Catalyst Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics 0 0 5 0 3.00
Catalyst Pharmaceuticals 0 0 4 0 3.00

Bicycle Therapeutics currently has a consensus price target of $19.00, suggesting a potential upside of 120.67%. Catalyst Pharmaceuticals has a consensus price target of $9.75, suggesting a potential upside of 113.82%. Given Bicycle Therapeutics’ higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Catalyst Pharmaceuticals.


Catalyst Pharmaceuticals beats Bicycle Therapeutics on 6 of the 10 factors compared between the two stocks.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.